PASITHEA THERAPEUTICS CORP (KTTA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.58-0.07%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KTTA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -71.3% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
KTTA — legal / regulatory event — Notice of Delisting or Failure to
Dated 2026-08-21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on February 20, 2026, Pasithea Therapeutics Corp. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for the prior 30 consecutive business days, the Company wa…
Why it matters: A new CEO can shift company direction. Positive changes may boost investor sentiment.
Watch forGood analyst reports or stock price rise follow the new CEO's announcements.
Also watch forBad market reaction or stock price drop after the CEO's first big announcements.
Why it matters: Advancing clinical development is important for growth. It shows the company's focus on its medical plan.
Supportive ifAn announcement of a new clinical trial or positive data from an ongoing trial.
Worry ifNo updates or delays in clinical trials for more than six months.
Why it matters: Fixing compliance issues is key to keeping the company's listing. Not fixing them could hurt operations.
Worry ifFixing Nasdaq compliance issues means the company can keep its listing.
Less concerning ifNot meeting Nasdaq listing rules could lead to delisting.
Why it matters: Better cash flow means stronger financial health. It shows management's skill in reducing losses.
Supportive ifQ2 cash flow from operations is positive or shows big improvement.
Worry ifCash flow from operations remains negative or worsens in Q2.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$237 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $556 loss on $10,000 · 5.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,704 loss on $10,000 · 27.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Managing losses is key for financial health. Better management means better cash flow.
Supportive ifOperating losses drop to below negative $3M in the next quarter.
Worry ifOperating losses stay above negative $10M for the next two quarters.
Why it matters: A new CEO can change company direction. Positive changes may boost investor confidence.
Supportive ifInvestors and analysts give positive feedback on the new CEO's plan.
Worry ifNegative reactions or lack of confidence in the new CEO's direction.
Why it matters: The new CEO's vision can impact the company's direction. It may lead to new growth opportunities.
Watch forA strategic plan announcement from the new CEO outlining future goals.
Also watch forThe new CEO has not shared a clear plan or vision.
Why it matters: Fixing compliance issues is important for keeping the company's listing. Not fixing them could hurt operations.
Worry ifPasithea said it has met Nasdaq rules.
Less concerning ifNasdaq may send more notices about non-compliance or risks of being delisted.
Why it matters: Operating losses impact cash flow and overall financial health. Investors will look for signs of improvement.
Worry ifThe Q2 earnings report shows smaller operating losses than before.
Less concerning ifThe Q2 earnings report shows larger operating losses than before.
Why it matters: Managing cash flow and losses is crucial for the company's financial health.
Worry ifOperating losses go down or cash flow becomes positive in the next quarters.
Less concerning ifOperating losses go up or cash flow stays negative.
Why it matters: Advancing PAS-004 is key for Pasithea's growth. Positive trial results could boost investor confidence.
Supportive ifPositive interim results were announced from the Phase 1 clinical trial for PAS-004.
Worry ifNegative results or delays in the Phase 1 clinical trial for PAS-004.